pubmed.ncbi.nlm.nih.gov

Dose dependence of treatment-related adverse events for immune checkpoint inhibitor therapies: a model-based meta-analysis - PubMed

  • ️Wed Jan 01 2020

Review

Dose dependence of treatment-related adverse events for immune checkpoint inhibitor therapies: a model-based meta-analysis

Boris Shulgin et al. Oncoimmunology. 2020.

Abstract

Programmed cell death-1 (PD-1) and/or cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) immune checkpoint inhibitor (ICI) treatments are associated with adverse events (AEs), which may be dependent on ICI dose. Applying a model-based meta-analysis to evaluate safety data from published clinical trials from 2005 to 2018, we analyzed the dose/exposure dependence of ICI treatment-related AE (trAE) and immune-mediated AE (imAE) rates. Unlike with PD-1 inhibitor monotherapy, CTLA-4 inhibitor monotherapy exhibited a dose/exposure dependence on most AE types evaluated. Furthermore, combination therapy with PD-1 inhibitor significantly strengthened the dependence of trAE and imAE rates on CTLA-4 inhibitor dose/exposure.

Keywords: Adverse events; immune checkpoint inhibitor; meta-analysis.

© 2020 The Author(s). Published with license by Taylor & Francis Group, LLC.

PubMed Disclaimer

Conflict of interest statement

BS, YK, AO, and KP are employees of M&S Decisions LLC, Moscow, Russia, which received funding from AstraZeneca to conduct this research and analysis; LC, GM, SA, RP, GD, GK, and GH are all employees of AstraZeneca.

Figures

Figure 1.
Figure 1.

Forest plots of grade 3/4 AEs for (a) CTLA-4 inhibitors and (b) CTLA-4 inhibitor + PD-1 inhibitor.

Figure 2.
Figure 2.

Dependencies of grade AEs upon ICI drug dose/exposure for (a) total trAEs, (b) gastrointestinal imAEs, and (c) hepatic imAEs.

Figure 3.
Figure 3.

Dependencies of AEs on ICI dose/exposure and baseline characteristics.

Similar articles

Cited by

References

    1. Gong J, Chehrazi-Raffle A, Reddi S, Salgia R.. Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations. J Immunother Cancer. 2018;6(1):8. doi:10.1186/s40425-018-0316-z. - DOI - PMC - PubMed
    1. Marrone K, Ying W, Naidoo J.. Immune-related adverse events from immune checkpoint inhibitors. Clin Pharmacol Ther. 2016;100(3):242–12. doi:10.1002/cpt.394. - DOI - PubMed
    1. Boutros C, Tarhini A, Routier E, Lambotte O, Ladurie FL, Carbonnel F, Izzeddine H, Marabelle A, Champiat S, Berdelou A, et al. Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination. Nat Rev Clin Oncol. 2016;13(8):473–486. doi:10.1038/nrclinonc.2016.58. - DOI - PubMed
    1. Michot JM, Bigenwald C, Champiat S, Collins M, Carbonnel F, Postel-Vinay S, Berdelou A, Varga A, Bahleda R, Hollebecque A, et al. Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur J Cancer. 2016;54:139–148. doi:10.1016/j.ejca.2015.11.016. - DOI - PubMed
    1. Nishijima TF, Shachar SS, Nyrop KA, Muss HB.. Safety and tolerability of PD‐1/PD‐L1 inhibitors compared with chemotherapy in patients with advanced cancer: a meta‐analysis. Oncologist. 2017;22(4):470–479. doi:10.1634/theoncologist.2016-0419. - DOI - PMC - PubMed

Publication types

MeSH terms

Substances

Grants and funding

This work was supported by AstraZeneca.